Filter Results:
(1,243)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
- February 2006 (Revised February 2009)
- Case
AIDS in Brazil
By: Rohit Deshpande and Ricardo Reisen de Pinho
Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra. View Details
Keywords: Price; Government and Politics; Health Care and Treatment; Health Disorders; Rights; Negotiation; Business and Government Relations; Pharmaceutical Industry; Brazil
Deshpande, Rohit, and Ricardo Reisen de Pinho. "AIDS in Brazil." Harvard Business School Case 506-062, February 2006. (Revised February 2009.)
- February 2002
- Case
Fighting AIDS and Pricing Drugs
In early 2001, makers of AIDS drugs were suing to prevent developing countries from violating their patents. The issue was driven by price. The developing countries could not afford the market price for these drugs. At the same time, the drug companies were reluctant... View Details
Keywords: Developing Countries and Economies; Patents; Price; Strategy; Globalized Markets and Industries; Pharmaceutical Industry
Gourville, John T. "Fighting AIDS and Pricing Drugs." Harvard Business School Case 502-061, February 2002.
- February 2002
- Case
NeuroTherapy Ventures: Catalyzing Neurologic Innovations
Discusses the impact of limited market size on epilepsy therapies and shows how an early-stage venture fund can catalyze faster development of new treatments. View Details
Keywords: Information Technology; Commercialization; Innovation and Management; Business Startups; Pharmaceutical Industry
Chesbrough, Henry W. "NeuroTherapy Ventures: Catalyzing Neurologic Innovations." Harvard Business School Case 602-124, February 2002.
- October 2000
- Supplement
Hans Fritz at Novartis Thailand (D): The First 18 Months
By: Michael Y. Yoshino and Carin-Isabel Knoop
Supplements the (A) case. View Details
Yoshino, Michael Y., and Carin-Isabel Knoop. "Hans Fritz at Novartis Thailand (D): The First 18 Months." Harvard Business School Supplement 301-055, October 2000.
- July 1999
- Supplement
Jan Eriksson of Novartis Indonesia
By: Christopher A. Bartlett and Carin-Isabel Knoop
A follow-up interview, in Summer 1998, with the protagonist of the Novartis Indonesia case series. He describes ongoing strategy and activities. View Details
Bartlett, Christopher A., and Carin-Isabel Knoop. "Jan Eriksson of Novartis Indonesia." Harvard Business School Video Supplement 899-509, July 1999.
- November 1999
- Supplement
"ACT UP": Peter Staley, An Interview with Professor Willis Emmons, November 17, 1995
Provides excerpts from an interview with Peter Staley of Act Up reflecting on the Wall Street protest against Burroughs Wellcome in the fall of 1989 and on the role and impact of AIDS advocacy and activism in general. View Details
Emmons, Willis M., III. "ACT UP": Peter Staley, An Interview with Professor Willis Emmons, November 17, 1995. Harvard Business School Video Supplement 700-501, November 1999.
- January 1989
- Case
Eli Lilly and Co.: The Beginning of a Journey in Manufacturing
Keywords: Pharmaceutical Industry
Wheelwright, Steven C. "Eli Lilly and Co.: The Beginning of a Journey in Manufacturing." Harvard Business School Case 689-014, January 1989.
- February 1999 (Revised August 2005)
- Teaching Note
BIOPURE Corporation (TN)
Teaching Note for (9-598-150). View Details
Keywords: Pharmaceutical Industry
- February 1995 (Revised March 1995)
- Teaching Note
Astra/Merck Group TN
By: Frank V. Cespedes
Teaching Note for (9-594-045). View Details
Keywords: Pharmaceutical Industry
- January 1993 (Revised November 1993)
- Case
Warner-Lambert Ireland: Niconil
By: John A. Quelch and Susan Smith
The marketing director of Warner-Lambert's Irish subsidiary is completing the marketing plan for the launch of Niconil, a transdermal skin patch to facilitate smoking cessation. View Details
Quelch, John A., and Susan Smith. "Warner-Lambert Ireland: Niconil." Harvard Business School Case 593-008, January 1993. (Revised November 1993.)
- April 1990 (Revised November 1992)
- Case
Population Services International: The Social Marketing Project in Bangladesh (Abridged)
By: James E. Austin
Population Services International (PSI) was a not-for-profit agency founded to disseminate family planning information and to market birth control products, primarily in less developed countries seeking to curb their population explosions. In 1976, PSI concluded an... View Details
Keywords: Conferences; Developing Countries and Economies; Information Publishing; Growth and Development Strategy; Marketing Strategy; Social Marketing; Agreements and Arrangements; Product; Nonprofit Organizations; Pharmaceutical Industry; Bangladesh; Washington (state, US)
Austin, James E. "Population Services International: The Social Marketing Project in Bangladesh (Abridged)." Harvard Business School Case 590-061, April 1990. (Revised November 1992.)
- April 1978
- Case
FTC and Listerine Antiseptic
Keywords: Business and Government Relations; Misleading and Fraudulent Advertising; Pharmaceutical Industry
Greyser, Stephen A. "FTC and Listerine Antiseptic." Harvard Business School Case 578-166, April 1978.
- February 1973 (Revised June 1973)
- Case
Listerine Antiseptic (A)
Greyser, Stephen A. "Listerine Antiseptic (A)." Harvard Business School Case 573-060, February 1973. (Revised June 1973.)
- September 1990 (Revised November 1991)
- Supplement
Merck & Co., Inc. (C)
Discusses the 1989 modified performance appraisal program by adding performance gradations and allowing for differences in employee rating distributions depending on the division performance for the year. The objective is to have students discuss the revisions in the... View Details
Murphy, Kevin J. "Merck & Co., Inc. (C)." Harvard Business School Supplement 491-007, September 1990. (Revised November 1991.)
- March 1999 (Revised January 2001)
- Case
Hans Fritz at Novartis Thailand (B): The First Six Months
By: Michael Y. Yoshino and Carin-Isabel Knoop
Supplements the (A) case. View Details
Yoshino, Michael Y., and Carin-Isabel Knoop. "Hans Fritz at Novartis Thailand (B): The First Six Months." Harvard Business School Case 399-124, March 1999. (Revised January 2001.)
- November 1978 (Revised January 1983)
- Case
Vick International Division: Tom McGuire
Explores the ways in which International Division management uses formal management systems in carrying out its roles in the management processes of one division of a diversified drug company. View Details
Keywords: Globalized Firms and Management; Business Divisions; Management Systems; Pharmaceutical Industry
Vancil, Richard F. "Vick International Division: Tom McGuire." Harvard Business School Case 179-068, November 1978. (Revised January 1983.)
- August 1989 (Revised October 2005)
- Case
James Burke: A Career in American Business (B)
By: Richard S. Tedlow and Wendy Smith
Covers the history of Tylenol from the autumn of 1982 through the second tampering incident in February 1986. Also deals with other developments in the history of Johnson & Johnson, especially the acquisition and divestiture of Technicare. View Details
Tedlow, Richard S., and Wendy Smith. "James Burke: A Career in American Business (B)." Harvard Business School Case 390-030, August 1989. (Revised October 2005.)
- 01 Mar 2012
- News
How to Close the Health Gap
real progress has been made over the last decade, thanks in part to funding from organizations such as the Bill & Melinda Gates Foundation and efforts by pharmaceutical companies and governments to make drugs available at little or no... View Details
- 01 Dec 2017
- News
2017 in Health Care: Telemedicine Has Arrived
telemedicine services available next year to employees in states that allow it. We’re going to see a lot more investment in this area, from both established health care companies and startups. What’s next in health care? “More constraints on drug price growth. Today,... View Details